OnKure Therapeutics, Inc.
NASDAQ:OKURBiotechnology
Healthcare
$2.76 +0.23%
+$0.01 today
- Market cap
- $111.79M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.30
52W Low $1.91High $5.38
Volume 0.14M
Average 0.37M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$51.83M
FY 2025 · Annual
Investing Cash Flow
-$46,000.00
FY 2025 · Annual
Financing Cash Flow
$163,000.00
FY 2025 · Annual
-99.9% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (39.77M) | (29.51M) | (35.31M) | (52.67M) | (59.52M) |
| Depreciation & Amortization | 50K | 387K | 560K | 662K | 830K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 48K | 199K | 4.53M | 11.63M |
| Change in Working Capital | (2.8M) | 2.12M | 6K | (3.95M) | (4.78M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 1.71M | (5.93M) | (4.55M) |
| Other Working Capital | (2.8M) | 2.12M | (1.71M) | 1.98M | (235K) |
| Other Non-Cash Items | 4.54M | 0 | 0 | 316K | 6K |
| Operating Cash Flow | (37.98M) | (26.95M) | (34.55M) | (51.12M) | (51.83M) |
| Capital Expenditures | (198K) | (1.13M) | (246K) | (52K) | (46K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (31.41M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 8.23M | 44.1M | 0 | 15.93M | 0 |
| Other Investing Activities | 0 | (44.1M) | 0 | 0 | 0 |
| Investing Cash Flow | (23.38M) | (1.13M) | (246K) | 15.87M | (46K) |
| Debt Repayment | 0 | 0 | 0 | 6M | 0 |
| Common Stock Issued | 132.41M | 340K | 65K | 58.91M | 203K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (1.38M) | (723K) | 51.22M | (40K) |
| Financing Cash Flow | 132.41M | 26.47M | 53.13M | 116.13M | 163K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 71.05M | (1.62M) | 18.33M | 80.89M | (51.71M) |
| Free Cash Flow | (38.18M) | (28.09M) | (34.79M) | (51.17M) | (51.87M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$59.5M
+ D&A$830.0K
+ Stock-Based Comp$11.6M
+ Deferred Tax$0
- Working Capital-$4.8M
+ Other Non-Cash$6.0K
= Operating Cash Flow-$51.8M
- Capex-$46.0K
= Free Cash Flow-$51.9M
Analysis
FY2025 free cash flow is -$51.9M. FCF conversion is 87.2% of net income. Operating cash flow was -$51.8M, with capex of -$46.0K. The largest bridge item is Stock-Based Comp at $11.6M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| SC 13G | SC 13G filing | Oct 7, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 23, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 23, 2026 |
Does OKUR generate free cash flow?
OnKure Therapeutics, Inc. (OKUR) generated -$51.87M of free cash flow in fiscal 2025.
How much operating cash flow does OKUR produce?
Operating cash flow was -$51.83M, before capital expenditures of $46,000.00.
Continue the stock analysis
Jump to another research area for this company.